26 results about "Azythromycin" patented technology

This invention belongs to the field of pharmaceutical crystallization technology, specifically relating to a crystallization process for small-particle-size azithromycin fumarate with low solvent residue. In existing processes, azithromycin fumarate crystallizes in alcohol solvents, often resulting in residual ethanol. This invention provides a crystallization process for azithromycin fumarate by adding a portion of fumaric acid to azithromycin, then adding azithromycin fumarate seed crystals, inducing crystallization through ultrasonication, continuing to add fumaric acid, and then concentrating under reduced pressure for isothermal crystal growth. The azithromycin fumarate crystals prepared by this method have a particle size distribution range of 15-30 μm, and the ethanol residue is reduced to below 0.5%, allowing for direct use in pharmaceutical preparations without further purification. This results in a high-quality, economically viable active pharmaceutical ingredient.

The invention discloses a novel Fe-C-N-coated Au material and a preparation method and application thereof.According to the Fe-C-N-coated Au material, iron monatomic nano-enzyme Fe-C-N serves as a core, gold nanoparticles are loaded on the surface, the Fe-C-N nanoparticles and a HAuCl4 aqueous solution are stirred at low temperature, then an ice-cold NaBH4 solution is slowly added into a mixed solution, and the Fe-C-N-coated Au material is obtained after reaction and treatment. The novel Fe-C-N-coated Au material disclosed by the invention can be used for rapidly and sensitively detecting the azithromycin or macrolide drug-resistant gene ermB.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

The application belongs to the technical field of antibacterial infection materials, and particularly relates to preparation and application of a biomimetic mineralization nanoparticle. x S y / AZM, which is obtained by fixing glucose oxidase (GOx) in FexSy nanoparticles hybridized with azithromycin (AZM) through a biomimetic mineralization strategy, and the nanoparticle GOx@Fe x S y / AZM serves as a therapeutic drug to catalyze a large amount of active oxygen free radicals (ROS) to improve inflammatory response in order to rapidly kill infectious microorganisms in the early stage of bacterial infection of a wound surface; and in the subsequent healing period, H2S released by the material and AZM will jointly promote the polarization of macrophages to M2 macrophages of a repair type to effectively mediate the tissue repair after a high inflammatory response, so that the ordered treatment of a high blood sugar infection wound surface is achieved.

The invention provides azithromycin water-free swallowing granules and a preparation method thereof, and belongs to the field of pharmaceutical preparations. The azithromycin water-free swallowing granules are prepared by mixing medicine-containing taste-masking pellets and taste-modifying granules. The medicine-containing taste-masking pellet sequentially comprises a medicine-containing pellet core, an isolating layer and a taste-masking layer from inside to outside, and the medicine-containing pellet core is prepared through a centrifugal pelleting process. The technical problem to be solved is that the azithromycin water-free swallowing granule can realize water-free rapid swallowing, keeps good taste in the whole process, remarkably improves medication convenience and patient compliance, and is particularly suitable for children and other groups with difficulty in swallowing.

The invention relates to an azithromycin hapten, an azithromycin artificial antigen and application thereof. The azithromycin A is used as an initial raw material, an active arm is introduced from a secondary amine terminal, all hydroxyl and tertiary amine structures of an azithromycin drug are completely reserved, the prepared hapten has a relatively good space structure, the electron cloud density of the hapten is basically consistent with that of an original drug, and the immunogenicity of the antigen is improved; the prepared azithromycin artificial antigen and the monoclonal antibody are high in specificity when being used for ELISA (enzyme-linked immunosorbent assay) detection, and the IC50 value is 0.03 g / L; a further established colloidal gold immunochromatography test strip can rapidly and conveniently realize qualitative detection of azithromycin, the sensitivity of the azithromycin in a standard solution is 0.5 g / kg, and the detection sensitivity of the azithromycin in a sample can reach 0.5 g / kg.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a navel therapy composition and a navel therapy preparation for preventing and treating abdominal pain caused by intravenous drip of azithromycin in children and a preparation method of the navel therapy composition and the navel therapy preparation. The technical key points are as follows: the fructus evodiae and the dysentery are combined according to a specific weight ratio, and are matched with pharmaceutic adjuvants such as a transdermal enhancer and an excipient to prepare special navel therapy dosage forms such as pills, cakes, patches and the like. According to the composition, by utilizing the characteristics that the Shenque acupoint (navel) epidermal cuticle is thin, the barrier function is weak, blood vessels are rich, and medicines are easy to disperse and absorb, adverse reactions such as gastrointestinal spasmodic pain, nausea and vomiting and the like caused by intravenous drip of azithromycin in children are effectively relieved through an administration mode of external application. Through clinical verification, the umbilical therapy preparation can remarkably reduce the incidence rate and severity score of stomachache, vomiting and diarrhea, and remarkably improve the treatment compliance of child patients.

The application discloses a synergistic bactericidal composition, comprising the following components: a toona sinensis extract: 16-2048 mu g / mL; a macrolide antibiotic: 0.0625-4096 mu g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotic is erythromycin or azithromycin. The application further discloses a use of the synergistic bactericidal composition in preparation of a medicine for treating skin and soft tissue infections. The composition provided by the application can convert the traditional macrolide antibiotics such as erythromycin and azithromycin which only have a bacteriostatic effect into a preparation which has clear bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the toona sinensis extract is combined with the antibiotic, a synergistic effect is exhibited, and the concentration of the toona sinensis extract and the antibiotic required when the toona sinensis extract and the antibiotic are used alone can be greatly reduced.

The present invention relates to an aminopyridone macrolide compound and the use thereof. Specifically disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits antibacterial, antimycoplasmal or antichlamydial activity, and can be used for preventing and / or treating related diseases caused by bacteria, mycoplasmas or chlamydias. Further, the compound of the present application can achieve an antibacterial activity comparable to or better than that of azithromycin or solithromycin at a lower dosage. Still further, the compound of the present application exhibits a superior antibacterial effect on Gram-positive bacteria. Even further, the compound of the present application exhibits a better inhibitory activity against mycoplasmas and a lower hepatotoxicity.

The invention discloses an azithromycin fumarate sustained-release tablet and a preparation method thereof, and particularly relates to the technical field of pharmaceutical preparations, and the sustained-release tablet comprises the following components based on 100% of the total mass of the sustained-release tablet: 30-50% of azithromycin fumarate, 5-20% of a wax retardant material, 20-40% of a high polymer material sustained-release matrix, 10-20% of a filler, 5-10% of a sweetener, 0.5-5% of a lubricating flow aid, and the balance of an adhesive. According to the invention, the dissolution and release degree of the medicine can be reduced, the peak concentration of the medicine is reduced, the peak valley fluctuation of the blood concentration is reduced, the adverse reaction of the medicine is slowed down, the effective blood concentration duration is prolonged, the clinical treatment effect of the medicine is improved, and the compliance, convenience and compliance of patient medication are also improved; the generation of drug resistance is reduced to the greatest extent.

The invention relates to a pyridone macrolide compound and application thereof. Specifically disclosed is a compound represented by formula I-1 or I-1 'or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has the activity of resisting bacteria, mycoplasma or chlamydia, and can be used for preventing and / or treating related diseases caused by bacteria, mycoplasma or chlamydia; furthermore, the antibacterial activity equivalent to or better than that of azithromycin or solificin can be achieved by using a lower dosage of the compound provided by the invention; furthermore, the compound provided by the invention has a better antibacterial effect on gram-positive bacteria; furthermore, the compound provided by the invention has better inhibitory activity and lower hepatotoxicity to mycoplasma.

The invention discloses a method for detecting the concentration of eight second-line antituberculous drugs based on HPLC-MS / MS. The eight second-line antituberculous drugs are divided into two groups for detection, one group takes levofloxacin as an internal standard substance, and an internal standard stock solution is prepared; the method comprises the following steps: detecting by taking standard substances of levofloxacin, ciprofloxacin and gatifloxacin as target substances; and in the other group, albendamide, deramanib, pritomanib, clarithromycin and azithromycin are used as target objects for detection. According to the method, the detection time is short, only 5 min is needed, and the detection time is saved; meanwhile, according to the method disclosed by the invention, the consumption of an organic solvent is reduced, so that the pollution to the environment is reduced, and the method has the characteristics of high accuracy and good precision, and provides the fastest and effective basis for clinical treatment.

The antimicrobial composition comprises a mixture or a reaction product of at least turmeric extract (TME), japonica extract (SJE) and Azithromycin (AZM), wherein the ratio of the mass of turmeric extract (TME) to the mass of japonica extract (SJE), mT\n.: msjE is in the range from 1 : 10 to 10: 1, and wherein the ratio of the sum of the masses of turmeric extract (TME) and japonica extract (SJE) to the mass of Azithromycin (AZM), (mTME + mSJE) : mAZM is in the range from 1 : 10 to 10: 1. The composition has an excellent antimicrobial effect. It can be embedded in products or placed on their surfaces and prevents or impedes the settling of microorganisms.

1. The name of the design product: packaging box (azithromycin tablets). 2. The use of the design product: storage and storage of medicines. 3. The design features of the design product: in the pattern. 4. The picture or photo that best indicates the design features: front view.

The application provides an azithromycin composition for injection and a preparation process thereof, and relates to the field of pharmaceutical preparations.The azithromycin composition for injection provided by the application is composed of azithromycin, citric acid and sodium hydroxide.The preparation process comprises the following steps: dissolving azithromycin, citric acid and sodium hydroxide in water for injection to obtain a medicinal solution; and vacuum freeze-drying the medicinal solution to obtain the azithromycin composition for injection; the vacuum freeze-drying process comprises the following steps in sequence: pre-freezing, sublimation drying and desorption drying; the application has the advantages that the prescription and accessories are few in types, the dosages are reasonable, the liquid preparation process is more optimal, the raw material dissolving time is short, the medicinal solution is stable, and no impurities are brought in by using activated carbon; the freeze-drying process cycle is short, the appearance of the freeze-dried product is beautiful, the re-dissolving time is short, the re-dissolved solution is more optimal in clarity, and the freeze-dried product has excellent stability, so that the clinical drug safety of the product is fundamentally ensured.

The present invention relates to the use of macrolide derivatives, such as azithromycin derivatives, for the treatment of eosinophilic granulocyte-related pathologies, such as chronic sinusitis with nasal polyp, eosinophilic granulocyte gastrointestinal disorders and hypereosinophilic granulocyte syndrome. Furthermore, the present invention relates to the use of macrolide derivatives, such as azithromycin derivatives, for reducing type 2 inflammation. The invention also relates to the use of the number of eosinophils for targeted therapeutic treatment.

The invention relates to the technical field of pharmaceutical preparations, in particular to an azithromycin freeze-dried preparation for children as well as a preparation method and application of the azithromycin freeze-dried preparation. The children azithromycin freeze-dried preparation contains azithromycin, anhydrous citric acid, a freeze-drying protective additive and an osmotic pressure regulator, the specification of a single bottle of the preparation is designed to be a small-dose unit (25mg, 50mg or 100mg), and accurate administration according to the body weight of children is facilitated. The preparation has the advantages of being accurate and flexible in dosage, rapid in redissolution, good in infusion stability, high in safety and the like, the clinical individualized medication requirement of the pediatric department is specially met, and the problems that when an existing adult preparation is used for children, the dosage is not accurate, waste is caused, and the safety of auxiliary materials is worry about are solved.

The present invention concerns the use of azithromycin derivatives in methods of improving immune system defences, specifically host defence mechanisms, particularly in response to bacteria, viral and fungal infections, such as respiratory infections, More particularly, but not exclusively, this invention concerns the use of (2S,3R,4S,6R)-2-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10,13- tetrahydroxy-3,5,8,10,12,14-hexamethyl-6-methyl-15-oxo-1-oxa-6-aza-11- cyclopentadecyloxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate for use in such methods.

The invention relates to a pyrimidine macrolide compound and application thereof. Specifically disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has the activity of resisting bacteria, mycoplasma or chlamydia, and can be used for preventing and / or treating related diseases caused by bacteria, mycoplasma or chlamydia; furthermore, the antibacterial activity equivalent to or better than that of azithromycin or solificin can be achieved by using a lower dosage of the compound provided by the invention; furthermore, the compound provided by the invention has a better antibacterial effect on gram-positive bacteria; furthermore, the compound provided by the invention has better inhibitory activity and lower hepatotoxicity to mycoplasma.

The invention discloses a synergistic bactericidal composition which comprises the following components: 16 g / mL-2048 g / mL of cortex albiziae extract, 10 g / mL-20 g / mL of plant extract, 10 g / mL-20. The content of the macrolide antibiotics is 0.0625 g / mL to 4096 g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotics are erythromycin or azithromycin. The invention also discloses application of the synergistic bactericidal composition in preparation of medicines for treating skin and soft tissue infection. According to the composition provided by the invention, macrolide antibiotics, such as erythromycin and azithromycin, which only have a bacteriostatic effect traditionally can be converted into preparations which have definite bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the cortex albiziae extract and the antibiotics are combined for use, an extremely strong synergistic effect is shown, and the concentrations required when the cortex albiziae extract and the antibiotics take effect independently can be greatly reduced.

The present invention relates to the production of a medical textile material having a nanofiber surface with transdermal drug release properties and coated with an azithromycin active substance by using a needle-type electrospinning method and an ultrasonic spray pyrolysis (USP) technique. A nanofiber medical textile material production method is disclosed, which comprises the steps of: preparing a polymer solution containing PVP (polyvinylpyrrolidone) at a concentration of 12 wt% and GEL (gelatin) at a concentration of 0.72 wt%; determining solution properties such as conductivity, viscosity and surface tension, producing nanofibers from the prepared polymer solution under optimum process parameters by means of an atmosphere-controlled horizontal needle-type fiber spinning (electrospinning) device, obtaining PVP / GEL nanofibers after the fiber spinning process, coating the obtained nanofibers (PVP / GEL nanofibers) with a drug active substance as a thin film by means of the USP (ultrasonic spray pyrolysis) method, and crosslinking the two polymers in two steps in order to facilitate the final application process of the drug release material, which can provide fast and slow release and maintain its stability in an aqueous environment by forming a sandwich structure.

This invention belongs to the technical field of azithromycin fumarate crystal form compounds, specifically relating to a novel hygroscopic azithromycin fumarate crystal form B with low hygroscopicity and its preparation method. Azithromycin fumarate itself has strong hygroscopicity, and improper storage will affect medication safety. To address the shortcomings of existing technologies, this invention provides a novel hygroscopic azithromycin fumarate crystal form B with low hygroscopicity and its preparation method. Using crude azithromycin fumarate as a raw material, it is dissolved in an alcohol solution and then subjected to ultrasonic induction and pressure treatment to form the novel crystal form B. Verification has shown that the novel crystal form B has lower hygroscopicity and higher temperature stability compared to existing crystal forms. Its preparation method has the advantages of being simple, reproducible, and easy for industrial production.

The present invention provides novel compounds which are derivatives of azithromycin and which have been found by the present inventors to have low antimicrobial activity, but significant epithelial barrier enhancing properties. The present invention further provides the use of the compounds as medicaments, in particular in the treatment or prevention of diseases or conditions caused by defects in epithelial cells or tissues or diseases or conditions which would benefit from enhancing or re-establishing epithelial barrier function, such as diseases of the respiratory tract.

The application belongs to the technical field of wastewater degradation, and specifically discloses a method for promoting photodegradation of azithromycin in water and application; after manganese porphyrin is added into wastewater containing azithromycin, the concentration of manganese porphyrin in each liter of wastewater is ensured to be 50 mg / L-100 mg / L, and the azithromycin is subjected to photodegradation under visible light conditions; the reaction condition of the degradation is simple, the input cost is low, and no toxic substances are generated in the process of promoting photodegradation of azithromycin, and the method is environment-friendly and non-polluting.

Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

The invention discloses a synergistic bactericidal composition, which comprises the following components: 256g / mL to 8192 g / mL of poplar bud flavin; the content of the macrolide antibiotics is 0.125 g / mL to 4096 g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotics are erythromycin or azithromycin. The invention also discloses an application of the synergistic bactericidal composition in preparation of a medicine for treating infection caused by staphylococcus aureus or methicillin-resistant staphylococcus aureus. According to the composition provided by the invention, macrolide antibiotics, such as erythromycin and azithromycin, which only have a bacteriostatic effect on staphylococcus aureus and drug-resistant strains thereof traditionally can be converted into preparations with definite bactericidal activity. After the poplatin and the antibiotics are combined for use, a remarkable synergistic effect is shown, and the concentration of the antibiotics required for realizing the sterilization effect can be greatly reduced.